322 related articles for article (PubMed ID: 12235267)
1. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
Yasuda K; Lan LB; Sanglard D; Furuya K; Schuetz JD; Schuetz EG
J Pharmacol Exp Ther; 2002 Oct; 303(1):323-32. PubMed ID: 12235267
[TBL] [Abstract][Full Text] [Related]
2. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.
Wandel C; Kim RB; Guengerich FP; Wood AJ
Drug Metab Dispos; 2000 Aug; 28(8):895-8. PubMed ID: 10901697
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
Wandel C; Kim RB; Kajiji S; Guengerich P; Wilkinson GR; Wood AJ
Cancer Res; 1999 Aug; 59(16):3944-8. PubMed ID: 10463589
[TBL] [Abstract][Full Text] [Related]
4. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes.
Schuetz EG; Umbenhauer DR; Yasuda K; Brimer C; Nguyen L; Relling MV; Schuetz JD; Schinkel AH
Mol Pharmacol; 2000 Jan; 57(1):188-97. PubMed ID: 10617694
[TBL] [Abstract][Full Text] [Related]
5. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
Zhang Y; Guo X; Lin ET; Benet LZ
Drug Metab Dispos; 1998 Apr; 26(4):360-6. PubMed ID: 9531525
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4.
Hochman JH; Chiba M; Yamazaki M; Tang C; Lin JH
J Pharmacol Exp Ther; 2001 Jul; 298(1):323-30. PubMed ID: 11408558
[TBL] [Abstract][Full Text] [Related]
7. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds.
Yumoto R; Murakami T; Nakamoto Y; Hasegawa R; Nagai J; Takano M
J Pharmacol Exp Ther; 1999 Apr; 289(1):149-55. PubMed ID: 10086998
[TBL] [Abstract][Full Text] [Related]
8. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
Huang L; Wring SA; Woolley JL; Brouwer KR; Serabjit-Singh C; Polli JW
Drug Metab Dispos; 2001 May; 29(5):754-60. PubMed ID: 11302944
[TBL] [Abstract][Full Text] [Related]
9. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.
Martínez C; García-Martín E; Pizarro RM; García-Gamito FJ; Agúndez JA
Br J Cancer; 2002 Sep; 87(6):681-6. PubMed ID: 12237780
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine.
Ketabi-Kiyanvash N; Weiss J; Haefeli WE; Mikus G
Addict Biol; 2003 Dec; 8(4):413-8. PubMed ID: 14690877
[TBL] [Abstract][Full Text] [Related]
12. Several major antiepileptic drugs are substrates for human P-glycoprotein.
Luna-Tortós C; Fedrowitz M; Löscher W
Neuropharmacology; 2008 Dec; 55(8):1364-75. PubMed ID: 18824002
[TBL] [Abstract][Full Text] [Related]
13. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure.
He H; Lyons KA; Shen X; Yao Z; Bleasby K; Chan G; Hafey M; Li X; Xu S; Salituro GM; Cohen LH; Tang W
Xenobiotica; 2009 Sep; 39(9):687-93. PubMed ID: 19569734
[TBL] [Abstract][Full Text] [Related]
14. Conferone from Ferula schtschurowskiana enhances vinblastine cytotoxicity in MDCK-MDR1 cells by competitively inhibiting P-glycoprotein transport.
Barthomeuf C; Demeule M; Grassi J; Saidkhodjaev A; Beliveau R
Planta Med; 2006 Jun; 72(7):634-9. PubMed ID: 16739070
[TBL] [Abstract][Full Text] [Related]
15. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
16. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.
Ward KW; Stelman GJ; Morgan JA; Zeigler KS; Azzarano LM; Kehler JR; McSurdy-Freed JE; Proksch JW; Smith BR
Drug Metab Dispos; 2004 Feb; 32(2):172-7. PubMed ID: 14744938
[TBL] [Abstract][Full Text] [Related]
17. Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe.
Chauret N; Tremblay N; Lackman RL; Gauthier JY; Silva JM; Marois J; Yergey JA; Nicoll-Griffith DA
Anal Biochem; 1999 Dec; 276(2):215-26. PubMed ID: 10603245
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
Barthomeuf C; Grassi J; Demeule M; Fournier C; Boivin D; Béliveau R
Cancer Chemother Pharmacol; 2005 Aug; 56(2):173-81. PubMed ID: 15824923
[TBL] [Abstract][Full Text] [Related]
19. In vitro complex formation and inhibition of hepatic cytochrome P450 activity by different macrolides and tiamulin in goats and cattle.
Zweers-Zeilmaker WM; Van Miert AS; Horbach GJ; Witkamp RF
Res Vet Sci; 1999 Feb; 66(1):51-5. PubMed ID: 10088712
[TBL] [Abstract][Full Text] [Related]
20. Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole.
Gibbs MA; Kunze KL; Howald WN; Thummel KE
Drug Metab Dispos; 1999 May; 27(5):596-9. PubMed ID: 10220488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
